Clinical Trials Directory

Trials / Completed

CompletedNCT02472418

Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches

A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Crossover Study Evaluating Efficacy of DFN-15 in Patients With Migraine Headache With or Without Aura

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
63 (actual)
Sponsor
Dr. Reddy's Laboratories Limited · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Crossover study of DFN-15 dose A versus DFN-15 dose B versus Placebo in the treatment of migraine headaches.

Conditions

Interventions

TypeNameDescription
DRUGDFN-15 Dose A (treatment A)DFN-15 Dose A administered
DRUGDFN-15 Dose B (treatment B)DFN-15 Dose B administered
OTHERPlacebo (treatment C)Placebo administered

Timeline

Start date
2015-06-05
Primary completion
2015-12-01
Completion
2016-05-05
First posted
2015-06-15
Last updated
2018-05-22

Locations

6 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02472418. Inclusion in this directory is not an endorsement.

Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches (NCT02472418) · Clinical Trials Directory